NASDAQ · Manufacturing · Surgical & medical instruments & apparatus
$12.15−$0.3100 (−2.49%) on the dayAs of the close; data may be delayed.
SKIN price, last 12 months
$31.80$9.94$12.15
Daily closes over the last 260 trading sessions: −56.6%. Highest close $31.80 on , lowest $9.94 on . Market data may be delayed.
Key stats
Previous close
$12.46
Open
$12.64
Day range
$12.05 – $12.82
52-week range
$9.68 – $33.00
Volume
123.1K
Avg volume (20 days)
84.5K
Market cap
$106.3M
Performance
1W−27.8%
1M+6.1%
3M−13.5%
6M−14.4%
YTD−57.7%
1Y−54.4%
vs S&P 500, 1Y−58.5 pts
Technicals and fundamentals
About SkinHealth Systems Inc. Class A
SkinHealth Systems Inc is a world-wide medical aesthetics company delivering an integrated ecosystem of clinically validated solutions designed to help consumers achieve superior skin health and support the success of providers. Its brands are Hydrafacial and SkinStylus.
Chart SKIN with indicators, scan for setups and get alerts
This page is open to everyone. A free ScanPro account adds the interactive parts, along with watchlists, paper trading with simulated money and the Academy's quizzes.
A full SKIN chart with indicator overlays, pattern markers and daily, weekly or intraday bars.
Scans of a whole index or list with 72 named conditions, 26 chart setups or a formula of your own.
Alerts and notifications when one fires on a stock you watch, on delayed market data.
Daily range (ATR)11.4%average true range, % of price
52w low $9.6852w high $33.00
Where price sits today against its own history. A description, not a forecast.
Valuation
P/E (trailing)—
P/E (forward)2.6
PEG0.93
Price / sales0.27
Price / book1.38
EV / EBITDA—
Company figures as of Nov 20, 2026.
Analysts
ConsensusHold3.0 on 1 (strong buy) to 5 (strong sell)
Analysts6
Average target$14.50+23.2% from today
Price targets are opinions and tend to lean optimistic.
Earnings
Next results, expectedaround Mar 11, 2027 (in 110 days)A year after its Mar 12, 2026 results release; the last came Nov 5, 2026. An estimate from its SEC filings, not a date the company announced.
Dividends & splits
No dividends on record.
Splits
Oct 14, 20261-for-20 (reverse)
Seasonality
-1.8
J
+3.6
F
-0.5
M
-17.8
A
+0.6
M
-2.5
J
-4.3
J
-1.6
A
-6.3
S
-14.6
O
-10.6
N
+0.1
D
Average return in each calendar month, Nov 30, 2021 to Oct 31, 2026. 5 years is 5 observations a month: too few to call a pattern, so read it as history, not a calendar to trade.
Year by year
Year
J
F
M
A
M
J
J
A
S
O
N
D
Year
2026
+8
−31
−14
−4
−9
−11
−1
−1
−7
−21
−64%
2025
+5
−12
−9
−26
+64
+17
−19
+35
−4
−28
+4
−6
−13%
2024
−6
+14
+33
−27
−32
−13
−4
−3
−20
+12
−8
+7
−49%
2023
+25
+11
+0
−9
−30
+4
−1
−26
−2
−33
−37
+21
−66%
2022
−41
+36
−13
−22
+9
−10
+4
−13
+2
−3
−6
−15
−62%
2021
−6
−7
−12%
Each year's monthly returns in %, the observations behind the averages. The last column compounds the year's months; a year the history only partly covers is faded.
Financials
As reported in the company's SEC filings. Latest: Q3 FY2026, ended Sep 30, 2026.
Free shows the latest quarter, the latest year and the last 12 months. Plus shows every period and the growth figures.See Plus
Figures are as each 10-Q and 10-K reported them, in the company's own fiscal calendar, not restated later. A company that changes how it reports a line can make one period look out of step with the rest. Growth compares the same period a year earlier and is left blank when the year before was a loss. Banks and insurers report no gross profit, so rows they don't file are left out. Every filing on SEC EDGAR
While the company beat earnings and revenue estimates significantly (89.39% EPS surprise), the stock has severely underperformed the market (down 60.3% YTD), and the company still posted a quarterly loss. The Zacks Rank #3 (Hold) rating and mixed estimate revisions suggest neutral near-term performance expectations despite the positive earnings surprise.
Mixed results with revenue declining year-over-year despite beating estimates, significant EPS improvement but still negative, strong consumables growth offset by weak EMEA and delivery systems performance, and stock underperforming the market. Zacks Rank #3 (Hold) rating reflects neutral outlook.
Despite the 9% single-day rally, the stock faces deteriorating fundamentals with massive year-over-year earnings losses (-1400%), declining revenues (-5%), and no positive earnings estimate revisions to support further upside. The reverse stock split, while addressing compliance issues, is a defensive measure. The Zacks Rank #3 (Hold) rating reflects limited confidence in sustained gains.
The company is successfully expanding its product portfolio into new European markets, leveraging existing distribution infrastructure and complementary technologies. This strategic expansion demonstrates growth momentum and diversification beyond its flagship Hydrafacial brand, positioning the company as a broader medical aesthetics ecosystem provider.
The company is expanding its product portfolio internationally into six European markets, leveraging existing infrastructure and provider relationships. This represents strategic growth and diversification of their medical aesthetics ecosystem beyond their flagship Hydrafacial brand, with plans for further distributor market expansion in 2027.
The company is successfully expanding its product portfolio into new European markets, leveraging existing infrastructure and partnerships. The launch of SkinStylus® represents strategic diversification beyond Hydrafacial®, with plans for further expansion through distributors in 2027. This demonstrates growth momentum and market confidence in the company's ability to execute its broader aesthetic medicine strategy.
Tone is the news provider's automated reading of each article for this stock. It describes the article, not what the price will do.
Figures describe the past, not what the price will do next. Educational tools, not investment advice.